WMT AG receives financing with participation from L-Bank’s “InnoGrowth BW” program
Marathon Beteiligungs AG is the lead investor, CARMA Funds also participates in €3.67 million round…
At WMT, we design precisely engineered small molecules to tackle some of the toughest remaining challenges in medicine. Through a novel, elegantly simple yet highly effective mechanism, we achieve therapeutic results where conventional therapies fall short.
Our mission is clear: to develop safe, transformative medicines that improve the lives of people suffering from severe and life-threatening diseases.
After years of research at Heidelberg institutes and at WMT, we discovered a groundbreaking new way to inhibit proliferating of overactivated cells: the Translational Trap.
Watch this video to learn how it works – and the wide range of applications it can unlock.
TT drugs block cancer cell proliferation with unmatched selectivity, offering new hope for patients with multiple myeloma and B-cell lymphoma.
TT allows us to suppress excessive inflammation without impacting healthy, unstimulated immune cells.
We are prioritizing treatments for rheumatoid arthritis and autoimmune vasculitis.
Viruses take over the protein-making machinery of infected host cells to produce numerous copies of themselves.
Our TT drugs can effectively block the replication of certain viruses.
Chief Executive Officer & Executive Board
Claus has earned his degree in biochemistry from the University of Tübingen and performed his PhD work in the group of Friedrich Bonhoeffer at the Max-Planck-Institue for Developmental Biology.
He was crucially involved in LION bioscience´s IPO in 2000 raising a European record sum of 220 M Euros. Together with Thomas Hoffmann he co-founded Phenex Pharmaceuticals AG in 2002 which became a very successful biotech company by closing two major asset sales to Janssen (2012) and Gilead (2014) with a total value of more than 600 million US $.
In summer 2020, Claus, together with eight experienced drug discovery scientists and Yves Guillermet from the business side co-founded WMT AG to continue his track record as a serial entrepreneur. Claus serves as the CEO of WMT.
Chief Scientific Officer
Iryna has 20 years’ experience in molecular biology with a focus on metabolism, transcriptional regulation and cancer. She has earned her PhD jointly from the EMBL and the Heidelberg University.
After several years of a postdoc and leading positions in academia (MPI, IMB and EMBL) she transitioned to industry. There she has been responsible for leading projects in the areas of transcriptional regulation, epigenetics and metabolism in oncology and inflammatory diseases.
In 2020, Iryna co-founded WMT AG, where she leads biology research.
Senior Vice President Chemistry
Christoph is a deeply experienced medicinal chemist with a rich history of optimizing new drugs and bringing them into the clinic to the patient.
Christoph is co-inventor on multiple therapeutic patents and has taken 4 new drugs into clinical development.
Chairman of Supervisory Board
Member of Supervisory Board
Deputy Chairman of the Supervisory Board
Member of Supervisory Board
Member of Supervisory Board
Member of Supervisory Board
WMT AG is a newly established biotech company in beautiful Heidelberg committed to developing novel game changing cancer therapeutics. Our founders team has a depth of 100 (wo)men years of experience in the field of drug discovery and has brought four new drug candidates into clinical development. Get the chance to participate in and contribute to the development of novel cancer therapeutics and apply to the current job openings.
No current job offerings
Bereich Molekularbiologie
Die WMT AG konzentriert sich auf die Entwicklung neuer niedermolekularer Wirkstoffe zur Behandlung von Krebs und Entzündungserkrankungen. Als wachsendes Biotech-Unternehmen in den frühen Jahren bieten wir dir die Möglichkeit, praxisnah mitzuwirken und unser Team aktiv zu verstärken.
Deine Aufgaben
Dein Profil
Wir bieten dir
Interessierte Studierende senden bitte ihr Motivationsschreiben zusammen mit Lebenslauf und Notenübersicht an jobs@wm-therapeutics.com
Marathon Beteiligungs AG is the lead investor, CARMA Funds also participates in €3.67 million round…
WMT tests substances from the “Translational Trap” platform for antiviral and antisepsis effects in cellular assays and animal models…
The Swiss foundation supports WMT´s philosophy of uniting excellent drug discovery skills with the idea of making drugs “affordable for the world”
WMT AG
Waldhofer Str. 104
69123 Heidelberg
Germany